These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2505468)

  • 1. Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
    Fontana L; De Sanctis G; De Rossi G; Bottari V; Petti MC; Ensoli F; Pasqualetti D; Mandelli F
    Acta Haematol; 1989; 82(1):1-6. PubMed ID: 2505468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective antibody-dependent and lectin-induced polymorphonuclear cytotoxicity in patients with myelodysplastic syndromes.
    Fontana L; De Sanctis G; Bottari V; Petti MC; Mandelli F
    Haematologica; 1990; 75(1):46-9. PubMed ID: 2338286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
    Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
    Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
    Galvani DW; Nethersell AB; Cawley JC
    Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms accounting for the impaired natural-killer cell activity in refractory anaemia with excess of blasts.
    Eliopoulos GD; Coulocheri SA; Eliopoulos AG; Katrinakis G; Karkavitsas N; Kyriakou D; Vaiopoulos G; Foudoulakis A
    Eur J Haematol; 1992 May; 48(5):237-43. PubMed ID: 1379537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
    Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
    Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
    Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.
    De Sanctis G; Bottari V; Frezzolini A; Ficcardi M; De Rossi G; Petti MC; Mandelli F; Fontana L
    Cancer Immunol Immunother; 1992; 34(6):414-8. PubMed ID: 1563019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
    Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes.
    Okabe M; Minagawa T; Nakane A; Sakurada K; Miyazaki T
    Scand J Haematol; 1986 Aug; 37(2):111-7. PubMed ID: 3489981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
    Omine M; Yamauchi H
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome.
    Kaiafa G; Papadopoulos A; Ntaios G; Saouli Z; Savopoulos C; Tsesmeli N; Kontoninas Z; Chatzinikolaou A; Tsavdaridou V; Klonizakis I; Hatzitolios A
    Ann Hematol; 2008 Apr; 87(4):257-62. PubMed ID: 18158579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interleukin 2 on myelodysplastic syndromes.
    Ogata K; Yokose N; Ito T; An E; Dan K; Nomura T
    Leuk Res; 1993 Feb; 17(2):137-42. PubMed ID: 8429690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.
    Ogata K; Yokose N; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
    Br J Haematol; 1994 Mar; 86(3):562-7. PubMed ID: 8043438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell function in severe combined immunodeficiency (SCID): evidence of a common T and NK cell defect in some but not all SCID patients.
    Peter HH; Friedrich W; Dopfer R; Müller W; Kortmann C; Pichler WJ; Heinz F; Rieger CH
    J Immunol; 1983 Nov; 131(5):2332-9. PubMed ID: 6415162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
    Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.
    Hejazi M; Manser AR; Fröbel J; Kündgen A; Zhao X; Schönberg K; Germing U; Haas R; Gattermann N; Uhrberg M
    Haematologica; 2015 May; 100(5):643-52. PubMed ID: 25682594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.